...
gild-img

Gilead Sciences Inc, Common Stock

GILD

NSQ

$93.4

+$0.83

(0.9%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$115.37B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
1028.5555
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.48M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
3.33%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$60.24 L
$98.08 H
$93.4

About Gilead Sciences Inc, Common Stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGILDSectorS&P500
1-Week Return1.47%-0.94%-2.6%
1-Month Return3.22%-5.08%-1.08%
3-Month Return11.2%-10.62%3.45%
6-Month Return32.05%-6.18%8.57%
1-Year Return16.82%1.98%24.3%
3-Year Return28.86%-0.93%25.58%
5-Year Return39.93%33.84%84.07%
10-Year Return4.42%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue22.45B24.69B27.30B27.28B27.12B[{"date":"2019-12-31","value":82.22,"profit":true},{"date":"2020-12-31","value":90.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.91,"profit":true},{"date":"2023-12-31","value":99.31,"profit":true}]
Cost of Revenue4.67B4.57B6.60B5.66B5.80B[{"date":"2019-12-31","value":70.82,"profit":true},{"date":"2020-12-31","value":69.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.7,"profit":true},{"date":"2023-12-31","value":87.93,"profit":true}]
Gross Profit17.77B20.12B20.70B21.62B27.12B[{"date":"2019-12-31","value":65.55,"profit":true},{"date":"2020-12-31","value":74.19,"profit":true},{"date":"2021-12-31","value":76.35,"profit":true},{"date":"2022-12-31","value":79.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin79.18%81.48%75.82%79.26%100.00%[{"date":"2019-12-31","value":79.18,"profit":true},{"date":"2020-12-31","value":81.48,"profit":true},{"date":"2021-12-31","value":75.82,"profit":true},{"date":"2022-12-31","value":79.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses13.49B10.19B10.61B10.65B11.81B[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":75.55,"profit":true},{"date":"2021-12-31","value":78.66,"profit":true},{"date":"2022-12-31","value":78.96,"profit":true},{"date":"2023-12-31","value":87.55,"profit":true}]
Operating Income4.29B7.03B7.41B7.33B7.61B[{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":92.43,"profit":true},{"date":"2021-12-31","value":97.38,"profit":true},{"date":"2022-12-31","value":96.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(122.00M)(3.39B)(129.00M)(2.45B)(1.66B)[{"date":"2019-12-31","value":-12200000000,"profit":false},{"date":"2020-12-31","value":-338600000000,"profit":false},{"date":"2021-12-31","value":-12900000000,"profit":false},{"date":"2022-12-31","value":-245100000000,"profit":false},{"date":"2023-12-31","value":-166400000000,"profit":false}]
Pre-Tax Income5.16B1.67B8.28B5.81B6.86B[{"date":"2019-12-31","value":62.33,"profit":true},{"date":"2020-12-31","value":20.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.23,"profit":true},{"date":"2023-12-31","value":82.86,"profit":true}]
Income Taxes(204.00M)1.58B2.08B1.25B(1.25B)[{"date":"2019-12-31","value":-9.82,"profit":false},{"date":"2020-12-31","value":76.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.09,"profit":true},{"date":"2023-12-31","value":-60.04,"profit":false}]
Income After Taxes5.36B89.00M6.20B4.57B8.11B[{"date":"2019-12-31","value":66.17,"profit":true},{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":76.5,"profit":true},{"date":"2022-12-31","value":56.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations5.36B89.00M6.20B4.57B5.83B[{"date":"2019-12-31","value":86.5,"profit":true},{"date":"2020-12-31","value":1.44,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.63,"profit":true},{"date":"2023-12-31","value":94,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income5.39B89.00M6.22B4.59B5.67B[{"date":"2019-12-31","value":86.52,"profit":true},{"date":"2020-12-31","value":1.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.77,"profit":true},{"date":"2023-12-31","value":91,"profit":true}]
EPS (Diluted)6.637.097.297.277.04[{"date":"2019-12-31","value":90.95,"profit":true},{"date":"2020-12-31","value":97.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.73,"profit":true},{"date":"2023-12-31","value":96.57,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GILD
Cash Ratio 0.43
Current Ratio 1.26
Quick Ratio 1.10

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GILD
ROA (LTM) 11.96%
ROE (LTM) 0.56%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GILD
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GILD
Trailing PE 1028.56
Forward PE 12.25
P/S (TTM) 4.08
P/B 6.24
Price/FCF 28
EV/R 4.72
EV/Ebitda 34.09
PEG 0.53

FAQs

What is Gilead Sciences Inc share price today?

Gilead Sciences Inc (GILD) share price today is $93.4

Can Indians buy Gilead Sciences Inc shares?

Yes, Indians can buy shares of Gilead Sciences Inc (GILD) on Vested. To buy Gilead Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GILD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Gilead Sciences Inc be purchased?

Yes, you can purchase fractional shares of Gilead Sciences Inc (GILD) via the Vested app. You can start investing in Gilead Sciences Inc (GILD) with a minimum investment of $1.

How to invest in Gilead Sciences Inc shares from India?

You can invest in shares of Gilead Sciences Inc (GILD) via Vested in three simple steps:

  • Click on Sign Up or Invest in GILD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Gilead Sciences Inc shares
What is Gilead Sciences Inc 52-week high and low stock price?

The 52-week high price of Gilead Sciences Inc (GILD) is $98.08. The 52-week low price of Gilead Sciences Inc (GILD) is $60.24.

What is Gilead Sciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Gilead Sciences Inc (GILD) is 1028.5555

What is Gilead Sciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Gilead Sciences Inc (GILD) is 6.24

What is Gilead Sciences Inc dividend yield?

The dividend yield of Gilead Sciences Inc (GILD) is 3.33%

What is the Market Cap of Gilead Sciences Inc?

The market capitalization of Gilead Sciences Inc (GILD) is $115.37B

What is Gilead Sciences Inc’s stock symbol?

The stock symbol (or ticker) of Gilead Sciences Inc is GILD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top